ACTIVE AGAINST COMMON PATHOGENS IN BOTH CABP AND ABSSSI

Pathogens shown to be susceptible to NUZYRA in clinical infections and in vitro1

CABP


GRAM-POSITIVE BACTERIA

  • Streptococcus pneumoniae
  • Staphylococcus aureus (methicillin-susceptible isolates)

GRAM-NEGATIVE BACTERIA

  • Haemophilus influenzae
  • Haemophilus parainfluenzae
  • Klebsiella pneumoniae

OTHER MICROORGANISMS

  • Chlamydophila pneumoniae
  • Legionella pneumophila
  • Mycoplasma pneumoniae

ABSSSI


GRAM-POSITIVE BACTERIA

  • Enterococcus faecalis
  • S aureus (methicillin-susceptible and resistant isolates)
  • Staphylococcus lugdunensis
  • Streptococcus anginosus grp. (includes S anginosus, Streptococcus intermedius, and Streptococcus constellatus)
  • Streptococcus pyogenes

GRAM-NEGATIVE BACTERIA

  • Enterobacter cloacae
  • K pneumoniae

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, Click Here.

Pathogens in which NUZYRA has shown in vitro activity1

GRAM-POSITIVE BACTERIA

  • Enterococcus faecium (vancomycin-susceptible
    and -resistant isolates)
  • Streptococcus agalactiae

GRAM-NEGATIVE BACTERIA

  • Enterobacter aerogenes
  • Escherichia coli
  • Citrobacter freundii
  • Citrobacter koseri
  • Klebsiella oxytoca
  • Moraxella catarrhalis

The safety and effectiveness of NUZYRA in treating clinical infections due to these microorganisms have not been established.

Get the In vitro Activity Guide
and learn more about the antimicrobial activity of NUZYRA

DOWNLOAD NOW